Latest Period
Q2 2026
CUSIP: 40637HAF6
Latest Period
Q2 2026
Institutions Reporting
52
Principal
$441,215,230
Price (% of par)
146.22%
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 52 institutions filings for Q2 2026.
Security key
40637HAF6
Latest holder period
Q2 2026
13F holders
52
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP 40637HAF6:
As of 30 Jun 2026, 52 institutional investors reported holding $441,215,230 in principal (par value) of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1.
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | $441,215,230 | $641,989,350 | -$4,838,429 | 146.22% | 52 |
| 2026 Q1 | $439,034,460 | $564,714,249 | +$8,065,864 | 128.33% | 49 |
| 2025 Q4 | $431,319,360 | $573,383,607 | -$303,578,944 | 132.8% | 55 |
| 2025 Q3 | $655,325,460 | $920,432,391 | +$102,237,538 | 140.75% | 63 |
| 2025 Q2 | $628,830,300 | $718,645,608 | -$27,561,128 | 114.08% | 74 |
| 2025 Q1 | $647,508,446 | $828,761,473 | +$4,645,168 | 128.11% | 77 |
| 2024 Q4 | $672,476,260 | $730,001,496 | -$62,779,579 | 108.09% | 77 |
| 2024 Q3 | $680,559,400 | $810,707,471 | +$105,250,543 | 118.98% | 75 |
| 2024 Q2 | $23,972,237,400 | $717,063,397 | -$3,930,381 | 111.16% | 72 |
| 2024 Q1 | $623,774,400 | $607,993,350 | -$28,940,823 | 97.4% | 70 |
| 2023 Q4 | $658,912,150 | $616,721,993 | -$3,988,874 | 93.09% | 72 |
| 2023 Q3 | $660,082,850 | $622,263,753 | +$620,529,779 | 93.71% | 64 |